Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene — a gene that can cause cancer — that may play an important role in colon cancer. Researchers also showed how this ...
Lumakras plus Vectibix improved overall survival and response rates in KRAS G12C-mutated metastatic colorectal cancer, despite not achieving statistical significance. The combination showed a 30% ...
Bottom Line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...
July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
ELI-002 2P vaccine targets KRAS mutation, showing reduced relapse risk and improved survival in pancreatic and colorectal cancer patients. Two-thirds of study participants exhibited a strong immune ...
Analysis of tumor microenvironmental features of primary and synchronous liver metastases from patients with colorectal cancer using a deep learning algorithm. Real-world analysis of the impact of ...
THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS ® (sotorasib) in combination with Vectibix ® ...
Among patients with KRAS G12C mutations, candidate primary resistance mutations were detected in many patients with colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), which may limit ...
Researchers from Japan report that they have characterized gene mutations in colorectal cancer (CRC) tumors with high tumor mutation burden that lack mutations in the major oncogenes. Their findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results